Novel Mutation in the Feline NPC2 Gene in Cats with Niemann–Pick Disease

Abstract

Niemann–Pick disease (NP) type C is an autosomal, recessive, and inherited neurovisceral genetic disorder characterized by the accumulation of unesterified cholesterol and glycolipids in cellular lysosomes and late endosomes, with a wide spectrum of clinical phenotypes. This study aimed to determine the molecular genetic alterations in two cases of felines with NP in Japan, a Siamese cat in 1989 and a Japanese domestic (JD) cat in 1998. Sanger sequencing was performed on 25 exons of the feline NPC1 gene and 4 exons of the feline NPC2 gene, using genomic DNA extracted from paraffin-embedded tissue specimens. The sequenced exons were compared with reference sequences retrieved from the GenBank database. The identified mutations and alterations were then analyzed using different prediction algorithms. No pathogenic mutations were found in feline NPC1; however, c.376G>A (p.V126M) was identified as a pathogenic mutation in the NPC2 gene. The Siamese cat was found to be homozygous for this mutation. The JD cat was heterozygous for the same mutation, but no other exonic NPC2 mutation was found. Furthermore, the JD cat had a homozygous splice variant (c.364-4C>T) in the NPC2 gene, which is not known to be associated with this disease. The NPC2:c.376G>A (p.V126M) mutation is the second reported pathogenic mutation in the feline NPC2 gene that may be present in the Japanese cat population.

The role of NPC2 gene in glioma was investigated based on bioinformatics analysis

“…Its coding protein NPC2 (NPC intracellular cholesterol transporter 2) is a protein coding gene containing a lipid recognition domain, which has been proved to play an important role in biological processes such as cholesterol metabolism [19] . Some studies have found that the mutation of this gene is associated with thyroid cancer [20] , gastric cancer [21] and Niemann-pick disease [22] . In order to further clarify the relationship between NPC2 gene and GBM and to guide the prognosis of GBM.…”